Tiziana's Nasal Anti-CD3 Shows Cognitive Benefits in Aging Models
Event summary
- Tiziana's preclinical data shows nasal anti-CD3 improves cognition in aging models by reducing neuroinflammation and enhancing neurogenesis.
- Study highlights reversal of key aspects of brain aging, including dampened microglial activation and reduced cellular senescence.
- Intranasal foralumab is being studied in multiple neurodegenerative indications, including MS, ALS, and Alzheimer’s disease.
- 14 patients with non-active secondary progressive multiple sclerosis (na-SPMS) have been dosed in an open-label Expanded Access Program.
The big picture
Tiziana’s findings align with growing interest in targeting neuroinflammation for cognitive decline, a space increasingly crowded with academic and industry efforts. The company’s intranasal approach offers a non-invasive alternative to traditional therapies, potentially broadening treatment options for aging populations. Success in clinical trials could position Tiziana as a key player in neurodegenerative disease management.
What we're watching
- Clinical Translation
- How preclinical cognitive benefits will translate into human trials for age-related disorders.
- Pipeline Expansion
- The pace at which Tiziana advances foralumab into additional neurodegenerative indications.
- Competitive Positioning
- Whether Tiziana can sustain differentiation with its nasal delivery approach amid broader neuroinflammation research.
Related topics